We are live on ! Find out more
TGTX icon

TG Therapeutics

45 hedge funds and large institutions have $27.7M invested in TG Therapeutics in 2013 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

27% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 11

7% more capital inflows, than outflows

Capital inflows: $11.8M | Capital outflows: $11.1M

0.85% more ownership

Funds ownership: 19.82% → 20.66% (+0.85%)

8% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 13

2% less funds holding

Funds holding: 46 → 45 (-1)

30% less call options, than puts

Call options by funds: $64K | Put options by funds: $91K

Holders
45
Holders Change
-1
Holders Change %
-2.17%
% of All Funds
1.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
14
Reduced
11
Closed
13
Calls
$64​K
Puts
$91​K
Net Calls
-⁠$27​K
Net Calls Change
-⁠$27​K

TGTX Hedge Fund Activity: Q4 2013 in Review

45 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q4 2013, worth a combined $27.7M — down 18% from $33.6M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of TGTX and 12 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 14 added.

The largest buyer was Baker Bros. Advisors, adding an estimated $6.46M. The largest seller was Jennison Associates, cutting an estimated $4.38M.

  • 45 institutional investors held TG Therapeutics (TGTX) as of Q4 2013, down from 46 in Q3 2013.
  • Funds reported $27.7M of TG Therapeutics stock for Q4 2013, down 18% quarter-over-quarter.
  • 12 funds opened new TG Therapeutics positions in Q4 2013 and 13 closed out, a net change of -1 holder.
  • The largest TG Therapeutics buyer in Q4 2013 was Baker Bros. Advisors, an estimated $6.46M added.
  • The largest TG Therapeutics seller in Q4 2013 was Jennison Associates, an estimated $4.38M sold.

Based on aggregated 13F filings for Q4 2013.